Quarterly report pursuant to Section 13 or 15(d)

DERIVATIVE LIABILITY (Details Narrative)

v3.21.2
DERIVATIVE LIABILITY (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Jul. 28, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Gain (Loss) on Sale of Derivatives $ 472,143 $ (211,000)   $ 670,143 $ (211,000)    
Loan Agreement [Member] | K2 HealthVentures LLC [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Secured debt $ 21,190,000     21,190,000     $ 50,000,000
Initial measurement of fair value       $ 126,857   $ 797,000  
Gain (Loss) on Sale of Derivatives     $ 670,143        
Loan Agreement [Member] | K2 HealthVentures LLC [Member] | Share-based Payment Arrangement, Tranche One [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Secured debt             $ 20,000,000